BlackRock Amends AngioDynamics Stake, Maintains Significant Holding
Ticker: ANGO · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1275187
| Field | Detail |
|---|---|
| Company | Angiodynamics Inc (ANGO) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock still owns a big chunk of AngioDynamics, signaling institutional confidence.**
AI Summary
BlackRock, Inc. filed an amended Schedule 13G/A on January 23, 2024, indicating its ownership of AngioDynamics Inc. common stock as of December 31, 2023. This filing updates previous disclosures, showing BlackRock continues to be a significant institutional holder in AngioDynamics. For investors, this matters because BlackRock's continued substantial stake signals confidence in AngioDynamics' long-term prospects, potentially influencing other institutional and retail investors.
Why It Matters
This filing confirms BlackRock's ongoing substantial investment in AngioDynamics, which can be seen as a vote of confidence from a major institutional investor.
Risk Assessment
Risk Level: low — This is a routine update from a major institutional investor, indicating no immediate significant risk or change in investment strategy.
Analyst Insight
An investor should note BlackRock's continued presence as a major shareholder, which might suggest stability, but should also conduct independent research into AngioDynamics' fundamentals and future prospects.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- AngioDynamics Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5)' sections.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., as indicated under '(1)Names of reporting persons. BlackRock, Inc.' and in the 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' section.
What is the subject company whose securities are being reported?
The subject company is ANGIODYNAMICS INC, as stated in the 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ANGIODYNAMICS INC' and '(Name of Issuer) ANGIODYNAMICS INC' sections.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified under '(Date of Event Which Requires Filing of this Statement) December 31, 2023'.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of AngioDynamics Inc. is 03475V101, as listed under '(CUSIP Number) 03475V101'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding ANGIODYNAMICS INC (ANGO).